Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 5Urinary Bladder Neoplasms 2Stomach Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Microsatellite Instability 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Glioma 1Gastroesophageal Cancer 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 5Nivolumab 3durvalumab 2atezolizumab 2relatlimab 1fludarabine phosphate 1fludarabine 1denileukin diftitox 1danvatirsen 1avelumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Irinotecan 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1IMM-101 1E7777 fusion protein 1Docetaxel 1Disulfides 1Diffusion Tensor Imaging 1Cyclophosphamide 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Turcot syndrome × relatlimab × Clear all
NCT03607890 2026-03-16

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
38 enrolled

Turcot syndrome, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡